Cantor Fitzgerald Comments on FATE FY2026 Earnings

Fate Therapeutics, Inc. (NASDAQ:FATE) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Fate Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the biopharmaceutical company will post earnings per share of ($0.73) for the year. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The company had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $1.18 million.

Several other research analysts also recently commented on FATE. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 15th. Barclays decreased their price target on shares of Fate Therapeutics from $10.00 to $2.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. Wells Fargo & Company dropped their price objective on shares of Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. Finally, Wedbush reiterated a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a report on Thursday, March 6th. Eight equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $4.14.

Fate Therapeutics Price Performance

NASDAQ FATE opened at $1.67 on Tuesday. The stock’s 50 day simple moving average is $1.16 and its 200-day simple moving average is $1.38. The company has a market cap of $191.39 million, a PE ratio of -1.01 and a beta of 2.23. Fate Therapeutics has a 1-year low of $0.66 and a 1-year high of $5.92.

Institutional Investors Weigh In On Fate Therapeutics

A number of hedge funds have recently modified their holdings of the company. CWM LLC raised its stake in Fate Therapeutics by 899.6% during the first quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 37,290 shares during the period. Graham Capital Management L.P. acquired a new stake in shares of Fate Therapeutics during the 4th quarter worth approximately $37,000. Brevan Howard Capital Management LP purchased a new stake in shares of Fate Therapeutics during the 4th quarter valued at approximately $41,000. FPC Investment Advisory Inc. acquired a new position in Fate Therapeutics in the fourth quarter valued at approximately $44,000. Finally, Caption Management LLC purchased a new position in Fate Therapeutics in the first quarter worth approximately $45,000. Hedge funds and other institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.